Loading...
•
Dec 31, 2025
Iovance Q4 2025 Earnings Report
Iovance reported fourth quarter 2025 net loss of 71904000 on total product revenue of 86771000, driven by Amtagvi growth and improved gross margin.
Key Takeaways
Iovance generated Q4 2025 total product revenue of 86771000, reflecting approximately 30% sequential growth, with gross margin of approximately 50%. Net loss for the quarter was 71904000 as the company continued investing in commercialization and R&D.
Total product revenue was 86771000 with ~30% quarterly growth.
U.S. Amtagvi revenue reached approximately 65000000 in Q4.
Gross margin improved to approximately 50%.
Net loss per share was -0.18 for the quarter.
Revenue by Segment
Forward Guidance
Iovance expects continued revenue growth from Amtagvi and operational improvements to drive margin expansion, with cash expected to fund operations into the third quarter of 2027.
Positive Outlook
- Approximately 30% quarterly revenue growth.
- Gross margin improved to approximately 50%.
- Cash runway expected into the third quarter of 2027.
- Expansion of authorized treatment centers.
- Global regulatory progress for Amtagvi.
Challenges Ahead
- Quarterly net loss of 71904000.
- High ongoing R&D investment of 71202000.
- Significant SG&A expenses of 36400000.
- Dependence on Amtagvi for growth.
- Continued operating losses as commercialization scales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...